Keyphrases
Patients with Cancer
100%
Immunological Effects
100%
Levamisole
100%
Interferon-γ
55%
Maximum Tolerated Dose
22%
Tumor Burden
22%
Soluble interleukin-2 Receptor (sIL-2R)
22%
Every Other Day
22%
Neopterin
22%
Immune Alterations
22%
Serum Levels
11%
Blood Samples
11%
Cancer Patients
11%
Monocytes
11%
In Cancer
11%
Phase I Study
11%
Beneficial Effects
11%
Flow Cytometric Analysis
11%
Subcutaneous Injection
11%
Melanoma
11%
Ongoing Clinical Trials
11%
Patients with Advanced Cancer
11%
Renal Cancer
11%
Multiple Dose
11%
Immunological Properties
11%
Completely Resected
11%
Adjuvant Trials
11%
Major Histocompatibility Antigen
11%
CD64
11%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Levamisole
100%
Gamma Interferon
55%
Neoplasm
22%
Maximum Tolerated Dose
22%
Soluble Interleukin 2 Receptor
22%
Neopterin
22%
Clinical Trial
11%
Subcutaneous Injection
11%
Melanoma
11%
Advanced Cancer
11%
Major Histocompatibility Antigen
11%
Nursing and Health Professions
Levamisole
100%
Gamma Interferon
55%
Malignant Neoplasm
22%
Tumor Volume
22%
Neopterin
22%
Maximum Tolerated Dose
22%
Soluble Interleukin 2 Receptor
22%
Blood Level
11%
Subcutaneous Injection
11%
Advanced Cancer
11%
Melanoma
11%
Major Histocompatibility Antigen
11%
Multiple Drug Dose
11%
Immunology and Microbiology
Levamisole
100%
Interferon Gamma
55%
Tumor Volume
22%
Interleukin 2 Receptor
22%
Neopterin
22%
Maximum Tolerated Dose
22%
Cancer Cell
11%
Blood Level
11%
Monocyte
11%
Major Histocompatibility Antigen
11%
Multiple Drug Dose
11%